



(51) International Patent Classification:

A23L 1/29 (2006.01) A61K 35/747 (2015.01)
A23L 1/30 (2006.01) C12N 1/00 (2006.01)

(21) International Application Number:

PCT/US2015/019618

(22) International Filing Date:

10 March 2015 (10.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14/249,548 10 April 2014 (10.04.2014) US
14/503,930 1 October 2014 (01.10.2014) US

(71) Applicant: MJN U.S. HOLDINGS LLC [US/US]; 2701
Patriot Blvd., 4th Floor, Glenview, Illinois 60026 (US).

(72) Inventors: CHICHOLOWSKI, Maciej.; 5020 Waterbury
Way, Fair Oaks, California 95628 (US). BERG, Brian.;
4221 Hungington Place, Evansville, Indiana 47725 (US).
RUDOLPH, Colin.; 156 Parker Avenue, San Francisco,

California 94118 (US). MCMAHON, Robert J.; 22 Arca-
dia Place, Cincinnati, Ohio 45208 (US). WAWORUNTU,
Rosaline.; 2662 Roxbury Road, Evansville, Indiana 47714
(US).

(74) Agent: CARTIGLIA, James R.; Patterson Intellectual
Property Law, P.C., Roundabout Plaza, 1600 Division St.,
Suite 500, Nashville, Tennessee 37203 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS OF USE FOR PROBIOTICS AND PREBIOTICS

FIG. 1



(57) Abstract: The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes *Lactobacillus rhamnosus* GG (LGG), galacto-oligosaccharide(s) (GOS) and polydextrose (PDX) to the subject. The combination of LGG, GOS, and PDX may exhibit additive or synergistic beneficial health effects when consumed. The nutritional compositions herein are suitable for administration to children and infants.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*